The Technical AnalystExchange: ASX Industry: Health Care Equipment & Services
CogState Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.19% $1.400
America/New_York / 3 mai 2024 @ 01:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 239.99 mill |
| EPS: | 0.0500 |
| P/E: | 28.00 |
| Earnings Date: | Feb 21, 2024 |
| SharesOutstanding: | 171.42 mill |
| Avg Daily Volume: | 0.101 mill |
| RATING 2024-05-02 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Sell | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 22.26x |
| Company: PE 28.00 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.52x |
| Company: PE 28.00 | industry: PE 54.21 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.55 (82.03%) $1.148 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.342 - 1.458 ( +/- 4.14%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.400 (2.19% ) |
| Volume | 0.0468 mill |
| Avg. Vol. | 0.101 mill |
| % of Avg. Vol | 46.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CGS.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CGS.AX
Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.